Patients with EGFR mutations and wild-type TP53 benefit more from the combination treatments of EGFR-TKIs and bevacizumab,[28] which may be related to the fact that TP53 mutations are a poor prognostic factor in patients with TKI and participate in primary drug resistance of EGFR-TKIs by small-cell lung cancer (SCLC) transformation.[29–31] The detection of NGS during the treatments showed continuous change of EGFR mutation, which may be related to the dynamic regulation of drug resistance phenotype. This evidence concerns the gene TP53 and small cell lung carcinoma.